cagrilintide+Semaglutide CS10 10mg*10vials

Smegglutide CS10 (10mg x 10 vials) is an upgraded mid-range, high-purity, lyophilized GLP-1 receptor agonist in the Smegglutide CS series. It is a mainstream standard iteration product developed based on the CS5 basic version. CS10 features optimized molecular stability and balanced bioactivity, providing moderate and effective GLP-1 activation, bridging the gap between low-dose basic experiments and high-intensity cutting-edge research. It is ideal for routine preclinical validation of glucose and lipid metabolism mechanisms, medium-dose gradient screening, routine efficacy modeling, and stable long-term metabolic intervention studies. With its balanced potency and excellent experimental compatibility, it has become the most widely used core research peptide in routine laboratory projects and the construction of standard metabolic models.

Product Functions and Research Value

Smegglutide CS10 stably activates the GLP-1 receptor, mimicking the body's physiological incretin response. This product focuses on routine and standardized metabolic studies, including moderately improving insulin sensitivity, stabilizing glycemic homeostasis, effectively suppressing appetite and maintaining satiety, and balancing interventions in lipid metabolism and fat accumulation. Compared to the low-dose CS5 version, CS10 exhibits stronger biological activity and more significant metabolic regulatory effects, producing clear and stable experimental phenotypes without causing overstimulation. Unlike the highly potent high-concentration SM series products, CS10 offers mild and controllable efficacy, low model loss rate, and high data reproducibility. It provides reliable and standardized experimental data for routine validation of insulin resistance, glucose and lipid metabolism disorders, and dietary regulation mechanisms.

Core Product Advantages

1. Balanced Upgrade and Iteration of CS10: The molecular structure has been optimized based on the basic version, moderately enhancing target binding activity and stability, achieving a perfect balance between experimental efficacy and safety.

2. The standard mainstream concentration of 10mg in the CS series addresses the insufficient efficacy of low-dose CS5 and the overstimulation issues of ultra-high concentration products, making it ideal for standard gradient experiments and routine batch modeling.

3. Mature Lyophilization Activity-Locking Process: Utilizing aseptic vacuum lyophilization technology, the bioactivity of the peptide is fully preserved. Each batch undergoes rigorous HPLC high-purity testing and is accompanied by a complete Certificate of Account (COA), ensuring ultra-low impurity content and stable batch consistency. 4. Practical Standardized Packaging: Each box contains 10 vials in a single integrated package, fully meeting the needs of routine laboratory experiments, academic research projects, standardized model batch validation, and wholesale procurement.

Semaglutide (CS10) 10mg*10 vials is a mid-range, balanced upgrade in the semaglutide CS series. It is a high-purity lyophilized GLP-1 receptor agonist and the mainstream iteration of the CS5 basic version. This product features optimized molecular stability, balanced enhancement of biological activity, and moderate yet efficient GLP-1 pathway activation, filling the specification gap between low-dose basic experiments and high-intensity cutting-edge scientific research. CS10 is suitable for mainstream research scenarios such as routine preclinical validation of glucose and lipid metabolism mechanisms, medium-dose gradient screening, routine pharmacodynamic modeling, and long-term stable metabolic intervention. With its balanced efficacy, broad applicability, and high experimental tolerability, it has become a core universal research peptide raw material for routine laboratory projects and the construction of standardized metabolic models.

Core Uses and Research Value of Peptide Drugs: CS10 can stably activate GLP-1 receptors in vivo, mimicking the physiological regulatory effects of natural incretin, and is mainly used for standardized, routine metabolic mechanism studies. Its main functions are to improve moderate insulin resistance, stabilize glycemic homeostasis, effectively suppress appetite, prolong satiety, and balance lipid metabolism, improving fat accumulation. Compared with low-dose CS5, CS10 has stronger biological activity, more significant glucose and lipid metabolism regulation, and a clearer and more stable experimental phenotype. Compared with high-concentration top-tier products in the SM series, CS10's efficacy is milder and more controllable, without overstimulating experimental models, significantly reducing model attrition rates, and exhibiting excellent experimental reproducibility and stability. This product provides standardized, high-efficiency metabolic mechanism studies.